In Taiwan’s drug registration process, intellectual property (IP) issues are handled through a patent linkage system under the Pharmaceutical Affairs Act. NDA holders must list relevant patents, and generic manufacturers cannot rely on protected data during the exclusivity period. Patent disputes are resolved before generic approvals, ensuring IP protection while promoting market competition.